Drugs Targeting MET

Emrelis (telisotuzumab vedotin-tllv) – approved for people with locally advanced or metastatic, non-squamous NSCLC who have high c-MET protein overexpression (meaning 50% or more of the cancer cells show strong staining for c-MET, as determined by an FDA-approved test) and have previously received systemic therapy.